I am the director of the Board of Governors Regenerative Medicine Institute Eye Program, professor of biomedical sciences and neurosurgery and professor of medicine at the David Geffen School of Medicine at UCLA. My background is in cancer research, and I have studied ocular diabetes for the past 25 years."
Delayed wound healing, erosions, and keratitis — the most serious complications of diabetes in the cornea — are treated only symptomatically. The Ljubimov Laboratory has described a number of markers altered in diabetic corneas. Using adenoviral gene therapy, the lab has been able to correct aberrant wound healing and several marker protein expression abnormalities in human organ-cultured diabetic corneas.
Learn more about the scientists, faculty members, investigators and other healthcare professionals of the Ljubimov Laboratory, whose dedicated efforts lead to groundbreaking discoveries.
Leszczynska A, Kulkarni M, Ljubimov AV, Saghizadeh M.
Sci Rep. 2018 Oct 11;8(1):15173.
Saghizadeh M, Kramerov AA, Svendsen CN, Ljubimov AV.
Stem Cells.2017 Oct;35(10):2105-2114.
Ljubimova JY, Sun T, Mashouf L, Ljubimov AV, Israel LL, Ljubimov VA, Falahatian V, Holler E.
Adv Drug Deliv Rev. 2017 Apr;113:177-200.